| Old Articles: <Older 29901-29910 Newer> |
|---|
 |
The Motley Fool
April 28, 2008
Brian Lawler |
Glaxo Getting By Weakening currency barely redeems the pharmaceutical's Q1 numbers.   |
The Motley Fool
April 28, 2008
Brian Lawler |
CV Therapeutics Feels the Love CV Therapeutics announces its second regulatory thumbs-up this month, after its lead drug Ranexa was essentially approved in the European Union. |
The Motley Fool
April 28, 2008
Brian Lawler |
Bristol-Myers' Comeback Continues The pharmaceutical's first quarter brings more robust results. |
The Motley Fool
April 28, 2008
Rich Smith |
Cash Flow Lags at L-3 The GAAP numbers look terrific, though at L-3 Communications. |
The Motley Fool
April 28, 2008
Ryan Fuhrmann |
Buyer's Remorse at RadioShack RadioShack posted a decent yet uninspiring first quarter. |
The Motley Fool
April 28, 2008
David Lee Smith |
No Vale of Tears Here Despite an earnings dip, there's a lot to like about Vale. |
The Motley Fool
April 28, 2008
Dan Caplinger |
Why Your Stocks Are Getting Hammered Is company management really on your side? |
The Motley Fool
April 28, 2008
Rick Aristotle Munarriz |
4 Stocks That Took a Hike Companies with growing yields can make you rich in more ways than the obvious. |
The Motley Fool
April 28, 2008
Tim Beyers |
Will the Feds Stand in the Way of P.A. Semi? Defense contractors may object to Apple's deal to acquire P.A. Semi. |
The Motley Fool
April 28, 2008
Rich Smith |
Ceradyne Surprises Ceradyne snaps its losing streak and trumps the Street's expectations for the first quarter of 2008. |
| <Older 29901-29910 Newer> Return to current articles. |
